Fluidigm Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Fluidigm stock.
View analyst ratings for Fluidigm or view top-rated stocks.

Wall Street analysts have given Fluidigm a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fluidigm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Fluidigm is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Fluidigm.

Fluidigm Co. (NASDAQ:FLDM) issued its quarterly earnings data on Thursday, May, 6th. The medical research company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.19. The medical research company had revenue of $32.79 million for the quarter, compared to analyst estimates of $32.86 million. Fluidigm had a negative trailing twelve-month return on equity of 28.73% and a negative net margin of 38.98%.
View Fluidigm's earnings history.

Fluidigm's stock was trading at $2.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLDM stock has increased by 131.9% and is now trading at $6.10.
View which stocks have been most impacted by COVID-19.

Fluidigm issued an update on its second quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $30 million-$32 million, compared to the consensus revenue estimate of $35.52 million.

3 Wall Street analysts have issued 1-year price targets for Fluidigm's shares. Their forecasts range from $7.00 to $16.00. On average, they expect Fluidigm's stock price to reach $11.67 in the next twelve months. This suggests a possible upside of 91.3% from the stock's current price.
View analysts' price targets for Fluidigm or view top-rated stocks among Wall Street analysts.

30 employees have rated Fluidigm CEO Chris Linthwaite on Glassdoor.com. Chris Linthwaite has an approval rating of 78% among Fluidigm's employees.

Some companies that are related to Fluidigm include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), Bio-Techne (TECH), PerkinElmer (PKI), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of FLDM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fluidigm investors own include Accelerate Diagnostics (AXDX), Himax Technologies (HIMX), Advanced Micro Devices (AMD), OPKO Health (OPK), Magnachip Semiconductor (MX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Pfizer (PFE), Dynavax Technologies (DVAX) and BioCryst Pharmaceuticals (BCRX).

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

Fluidigm's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.34%), Primecap Management Co. CA (7.23%), Neuberger Berman Group LLC (5.84%), Geode Capital Management LLC (1.69%), Nuveen Asset Management LLC (1.67%) and Paradigm Capital Management Inc. NY (1.66%). Company insiders that own Fluidigm stock include Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite.
View institutional ownership trends for Fluidigm.

FLDM stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Alyeska Investment Group L.P., Paradigm Capital Management Inc. NY, Neuberger Berman Group LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, and D. E. Shaw & Co. Inc..
View insider buying and selling activity for Fluidigm or view top insider-selling stocks.

FLDM stock was bought by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Samjo Capital LLC, BlackRock Inc., Morgan Stanley, UBS Group AG, PDT Partners LLC, SkyOak Wealth LLC, and Perkins Capital Management Inc.. Company insiders that have bought Fluidigm stock in the last two years include Nicolas Barthelemy, Samuel D Colella, and Stephen Christopher Linthwaite.
View insider buying and selling activity for Fluidigm or or view top insider-buying stocks.

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLDM stock can currently be purchased for approximately $6.10.

Fluidigm has a market capitalization of $457.27 million and generates $138.14 million in revenue each year. The medical research company earns $-53,020,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

Fluidigm employs 627 workers across the globe.

The official website for Fluidigm is www.fluidigm.com.

Fluidigm is headquartered at 2 Tower Place Ste 2000, South San Francisco CA, 94080.

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]